Economic Times6/18/2026Business1 min readIndia
FTC Mandates Aurobindo Pharma Divest Four Drug Products for Lannett Acquisition
Quick Look
The U.S. Federal Trade Commission (FTC) requires Aurobindo Pharma to sell four generic drug products to finalize its $250 million acquisition of Lannett Company Inc., preventing anti-competitive issues.
AI-generated summary
Why It Matters
The U.S. Federal Trade Commission (FTC) is reviewing mergers and acquisitions to prevent anti-competitive practices in the market.
Font size
The U.S. Federal Trade Commission is requiring Aurobindo Pharma Limited to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc., the agency said on Thursday in a statement.
This action is a condition for Aurobindo Pharma to finalize its acquisition of Lannett Company Inc., ensuring no anti-competitive issues arise from the deal.
Open Questions
- Which specific four drug products must be divested?
- Who is the intended buyer of the divested products?
Related Topics
This article was originally published by Economic Times.
